Inhibition of Xanthine Oxidase Protects against Sepsis-Induced Acute Kidney Injury by Ameliorating Renal Hypoxia

Ting-ting Wang, Yi-wei Du, Wen Wang, Xiang-nan Li, and Hong-bao Liu

Department of Nephrology, Tangdu Hospital, Air Force Military Medical University (Fourth Military Medical University), Xi’an 710038, China

Correspondence should be addressed to Hong-bao Liu; xjsnlhb@fmmu.edu.cn

Received 30 January 2022; Revised 15 June 2022; Accepted 1 July 2022; Published 15 July 2022

Academic Editor: Karolina Szewczyk-Golec

Copyright © 2022 Ting-ting Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Xanthine oxidase (XO) utilizes molecular oxygen as a substrate to convert purine substrates into uric acid, superoxide, and hydrogen peroxide, which is one of the main enzyme pathways to produce reactive oxygen species (ROS) during septic inflammation and oxidative stress. However, it is not clear whether XO inhibition can improve sepsis-induced renal hypoxia in sepsis-induced acute kidney injury (SI-AKI) mice. In this study, pretreatment with febuxostat, an XO-specific inhibitor, or kidney knockdown of XO by shRNA in vivo significantly improved the prognosis of SI-AKI, not only by reducing the levels of blood urea nitrogen, serum creatinine, tumor necrosis factor-α, interleukin-6, and interleukin-1β in peripheral blood but also by improving histological damage and apoptosis, reducing the production of ROS, and infiltrating neutrophils and macrophages in the kidney. More importantly, we found that pharmacological and genetic inhibition of XO significantly improved renal hypoxia in SI-AKI mice by a hypoxia probe via fluorescence staining. This effect was further confirmed by the decrease in hypoxia-inducible factor-1α expression in the kidneys of mice with pharmacological and genetic inhibition of XO. In vitro, the change in XO activity induced by lipopolysaccharide was related to the change in hypoxia in HK-2 cells. Febuxostat and XO siRNA significantly relieved the hypoxia of HK-2 cells cultured in 2% oxygen and reversed the decrease in cell viability induced by lipopolysaccharide. Our results provide novel insights into the nephroprotection of XO inhibition in SI-AKI, improving cell hypoxia by inhibiting XO activity and reducing apoptosis, inflammation, and oxidative stress.

1. Introduction

Sepsis is the leading cause of acute renal injury (AKI) and is associated with increased morbidity and mortality in intensive care units [1, 2]. Palliative interventions such as fluid resuscitation, antibiotics, vasopressin, and renal replacement therapy are recommended to treat sepsis-induced AKI (SI-AKI) patients and wait passively for the kidney function to recover [3–5]. The experimental AKI induced by lipopolysaccharide (LPS), a key component of the outer membrane of gram-negative bacteria, is commonly used in vivo model closely recapitulating SI-AKI in humans, which hosts a complex inflammatory milieu comprising neutrophils, macrophages, epithelial cells, reactive oxygen species (ROS), proinflammatory mediators, and enzymes [6, 7]. An in-depth understanding of the SI-AKI pathophysiology is of great benefit to formulating effective mechanism-mediated treatment strategies.

Xanthine oxidase (XO) is one of the main enzyme pathways that produce ROS during oxidative stress and inflammation. It utilizes molecular oxygen to catalyze the oxidation of purine substrates (such as hypoxanthine and xanthine) to uric acid and generates superoxide (O2−) and hydrogen peroxide (H2O2) [8, 9]. XO has been suggested to participate in the pathogenesis of acute organ injury, including SI-AKI. Its activity and expression can be upregulated by various inflammatory stimuli, such as LPS, cytokines, and hypoxia [10–16]. Febuxostat, a selective and potent inhibitor of XO, can alleviate AKI, which may be related to antioxidant stress, anti-inflammation, and antiendoplasmic reticulum
stress and reducing uric acid production [17–19]. The protective role of febuxostat in animal models of SI-AKI has only recently been reported. Ramos and his colleagues [20] found that febuxostat, rather than allopurinol, improved renal function in experimental SI-AKI animals induced by LPS. The mechanism may be associated with antioxidant, anti-inflammatory, and antiapoptotic effects. Similarly, Ibrahim et al. [21] confirmed the protective effect of febuxostat on liver and kidney injuries in sepsis after cecal ligation through its antioxidant, anti-inflammatory, and antiapoptotic properties and the weakening of the c-Jun N-terminal kinase signaling pathway.

In addition to the inflammatory cascade and oxidative stress, renal ischemia/hypoxia is emerging as a common pathophysiological feature of SI-AKI, an essential driver in the transition and/or propensity for the progression from AKI to chronic kidney disease (CKD) [22, 23]. Based on the characteristic that XO utilizes molecular oxygen to catalyze purine substrates, we hypothesize that downregulation of XO can alleviate local hypoxia in renal tissue of the SI-AKI model, which has not been reported thus far. Therefore, this study is aimed at exploring the effects and potential mechanisms of XO inhibition on LPS-induced renal hypoxia in SI-AKI mice.

2. Materials and Methods

2.1. Chemicals and Reagents. LPS (Escherichia coli serotype O55:B5, L2880) was obtained from Sigma-Aldrich (USA). F4/80 (cat no. 29414-1-AP) and myeloperoxidase (MPO, cat no. 22225-1-AP) antibodies were from Proteintech (Wuhan, China), and hypoxia-inducible factor-1α (HIF-1α) antibody (cat no. BF8002) was from Abingdon Biologicals (Jiangsu, China). XO (cat no. sc-398548) antibody was from Santa Cruz (USA). The XO activity assay kit (cat no. KTB1070), goat anti-mouse IgG H&L (DyLight 488) (cat no. A23610), goat anti-mouse IgG HRP (cat no. A21010) were purchased from Abbkine (Wuhan, China). Pimonidazole HCl and anti-pimonidazole mouse antibody was purchased from Hypoxprobe (USA). ELISA kits for tumor necrosis factor-α (TNF-α, cat no. BMS607-3), interleukin-6 (IL-6, cat no. KMC0061), and IL-1β (cat no. KMC0061) were from Thermo Fisher Scientific (USA). The fluorescein (FITC) TUNEL Cell Apoptosis Detection Kit was from Servicebio (cat no. G1501, Wuhan, China). Dihydroethidium (DHE) for probing superoxide radicals was purchased from Beyotime (cat no. S0063, Shanghai, China).

2.2. Animals and Experimental Protocol. All animal experiments were conducted in strict accordance with the Guidelines for Care and Use of Laboratory Animals and were permitted by the Animal Welfare and Ethics Institution of the Fourth Military Medical University. Male C57BL/6 mice aged 6–8 weeks, weighing 20–25 g, were raised in the SPF laboratory of the Animal Experiment Center of the Air Force Military Medical University (Fourth Military Medical University). They were randomly divided into three groups: control (received water by gavage) group (n = 10), LPS (10 mg/kg dissolved in sterile deionized water) only group (n = 10), and LPS+febuxostat (Feb, 10 mg/kg/day dissolved in saline) (n = 10). The mice were given febuxostat by gavage every 24 h for 7 days, followed by intraperitoneal injection of LPS. For XO knockdown in vivo, we constructed an AAV vector carrying XO shRNA (pAAV-shXO) with a target sequence of 5′ AAGTGTAGCAATCGCGTCC 3′ (Shanghai Genechem Co., Ltd). Mice were divided into two groups: LPS+pAAV-shNC (LPS+Ctrl-shR) and LPS+pAAV-shXO (LPS+XO-shR) (n = 10). AAV injection was conducted according to the previous research [24]. Briefly, mice were anesthetized with 50 mg/kg sodium pentobarbital, the abdominal hair of the mice was removed with a shaver, and the mice were fixed in a supine position on the operating table with tape. Make a longitudinal incision about 2.0 cm long along the midline of the abdomen below the costal margin. Then, renal vein was isolated and clamped, and 50 μl of 1× PBS containing 1E + 11 V.G. of AA was slowly injected using a 30 G needle. The clamp was removed after 15 min postinjection, and the incision sutured. Three weeks later, LPS was administered to induce SI-AKI in mice. Animals were ethically sacrificed by administrating pentobarbital sodium (Sigma-Aldrich, USA) at 24 h after LPS injection, and whole blood and kidneys were collected for further analysis.

2.3. Blood Physiochemical Assays. The whole blood collected from the eyeballs was centrifuged at 4°C and 4000 rpm for 10 min to acquire the serum sample. The levels of serum creatinine (Scr, cat no. C011-2-1) and blood urea nitrogen (BUN, cat no. C013-2-1) were measured according to the manufacturer’s instructions using the creatinine and urea nitrogen assay kit (Nanjing Jiancheng, China).

2.4. Renal Histopathology. Kidney tissues were carefully separated, washed with ice-cold stroke-physiological saline solution, and stored in 4% paraformaldehyde. Hematoxylin and eosin (H&E) staining of paraffin-embedded kidney tissue slices was performed, and a double-blind method was utilized to assess the damage to renal tubular epithelial cells. H&E-stained sections were scored by calculating the percentage of tubules in corticomedullary junction that displayed cell necrosis, loss of brush border, cast formation, and tubular dilation as follows: 0, none; 1, <10%; 2, 11–25%; 3, 26–45%; 4, 46–75%; and 5, >76%. At least 10 randomly selected areas per mouse were assessed. The scores of ten fields per kidney section were averaged and used as the score of individual mouse kidneys.

2.5. Determination of XO Activity and Expression in Serum and Kidneys. After renal tissue homogenization, kidney XO activity was detected according to the manual instructions, and the XO activity in the serum was detected at the same time. XO expression in renal tissue was further detected by immunofluorescence. Briefly, kidney tissues were sliced into 5 μm sections, stained with XO antibody (1:100) for 18 h at 4°C, washed with phosphate buffered saline with Tween 20 (PBST), incubated with goat anti-mouse IgG (DyLight 488) (1:3000), and stained for 1 h at room temperature in the
dark. After washing with PBST, DAPI solution was added to stain the nucleus, and photos were taken with a laser confocal microscope (Leica SP8).

2.6. Determination of Hypoxia in Kidneys. Hypoxprobe, the component of which is pimonidazole hydrochloride, has been an effective approach to assessing hypoxia in cells [25]. Pimonidazole hydrochloride could be reduced, activated, and combined with thiol groups from peptides or proteins which could be detected with goat anti-mouse hypoxprobe antibody. Twenty-four hours after the SI-AKI model was established, and the mice were injected intraperitoneally with 60 mg/kg hypoxprobe and anesthetized with 50 mg/kg sodium pentobarbital 2 h later. The kidney tissues were collected and stored at -80°C. Kidney tissues were sliced into 5 μm sections, stained with goat anti-mouse hypoxprobe antibody (1:200) for 18 h at 4°C. Kidney slices were washed with PBST; then, goat anti-mouse IgG (DyLight 649) (1:3000) was added and stained for 1 h at room temperature in the dark. After washing with PBST, DAPI solution was added to stain the nucleus, and photos were taken with a laser confocal microscope (Leica SP8).

2.7. Western Blot Analysis. Equal amounts of protein from HK-2 cells or kidney tissue lysates were loaded and separated using 10% sodium dodecyl sulfate (SDS) polyacrylamide gels and transferred to polyvinylidene fluoride membranes (cat no. IPVH00010, Millipore, USA). The membranes were incubated with 5% nonfat milk for 1 h at room temperature and probed with HIF-1α or XO primary antibody for 18 h at 4°C, followed by a peroxidase-conjugated secondary antibody. Antibody-antigen complexes were detected using an ECL system (cat no. P0018AS, Beyotime, Shanghai, China). The intensity of each band was measured using ImageJ. The results were normalized to the intensity of beta-actin for standardization.

2.8. ROS Detection in Kidneys. Dihydroethidium (DHE) was used to detect the ROS levels in the renal tissues, as previously reported [26]. The renal tissues were immersed in saccharose (30% w/v), embedded at the optimal cutting temperature in the dark. After washing with PBST, DAPI solution was added to stain the nucleus, and photos were taken with a laser confocal microscope (Leica SP8).

2.9. Macrophages and Neutrophils Infiltrated the Kidney Tissues. Tissues were fixed with 4% paraformaldehyde and subsequently processed for immunofluorescence staining. MPO and F4/80 staining was performed after antigen retrieval (1% SDS for 3 min). MPO- and F4/80+ cells were quantified by counting the number of stained cells per field. We collected 10–15 images of a kidney from each animal at 400x magnification with a laser confocal microscope (Leica SP8).

2.10. Cytokine Analysis. The concentrations of the cytokines TNF-α, IL-6, and IL-1β in serum were measured with mouse TNF-α, IL-6, and IL-1β ELISA kits according to the instructions.

2.11. Kidney Terminal Deoxynucleotidyl Transferase dUTP Nick-End Labeling (TUNEL) Assay. Kidney tissue TUNEL analysis was conducted in accordance with our previous research [27]. Briefly, kidney tissues were fixed with 4% paraformaldehyde (PFA) for 24 h at room temperature, followed by dehydration and paraffin embedding. Tissues were cut into 5 μm sections for immunofluorescence staining. The sections were incubated with TdT enzyme solution for 90 min at 37°C. Then, FITC-12-dUTP was added and incubated for 30 min at 37°C. The reaction was terminated by incubation in stop/wash buffer for 30 min at 37°C. The number of TUNEL-positive cell nuclei and the total numbers of cell nuclei stained with DAPI were counted in 10 random areas, and the percentages of the numbers of TUNEL-positive nuclei to the numbers of total cell nuclei were then calculated.

2.12. Cells and Experimental Protocol. Cell culture experiments were performed using HK-2 cells, a human kidney proximal tubular cell line, which was purchased from the American Type Culture Collection. HK-2 cells at a concentration of 5 × 10^3/well in 96-well plates were cultured with or without LPS (10 μg/ml) in a trigas incubator (Thermo Fisher Scientific, USA) under 21% O2 or 2% O2 for 6 h in the presence or absence of febuxostat (100 μM). Then, we added 10 μL CCK-8 (Dojindo, Japan) to each well and measured the optical density (OD) values at 450 nm after 1 h of incubation. For hypoxia condition evaluation, HK-2 cells were thus divided into three groups: control, LPS (10 μg/ml), and LPS (10 μg/ml) plus febuxostat (100 μM). After administration of LPS and febuxostat, cells were incubated for 6 h. For XO knockdown analysis, HK-2 cells were transfected with siRNA of XO (XO-siR) or negative control (Ctrl-siR) using Lipofectamine® 2000 (Invitrogen) according to the manufacturer’s protocol. The target sequence of si-XO was 5’-GGCATTTGAGATGAAGTTCA-3’. The oligonucleotide dose used was 100 nM. All transfections were transient. Thirty-six hours later, the cells were treated with LPS (10 μg/ml) with or without 2% oxygen. Then, 150 μM pimonidazole HCl was added to the cells 1 h before being harvested for hypoxia evaluation, after fixation with 4% paraformaldehyde (PFA) for 20 min at room temperature. Anti-pimonidazole mouse antibody was incubated with the cells at 4°C for 18 h. Afterward, goat anti-mouse DyLight 488 antibody was added and incubated for 1 h at room temperature in the dark. Finally, confocal imaging was conducted with a Leica SP8 confocal microscope. For XO activity analysis, HK-2 cells at a concentration of 5 × 10^4/well in 6-well plates were cultured with or without LPS (10 μg/ml) in a trigas incubator under 21% O2 or 2% O2 for 6 h in the presence or absence of febuxostat (100 μM) or siXO transfection. After that, the cells were harvested for the XO activity assay conducted according to the assay kit instructions.
Fibroxanthyl (feb): 10 mg/kg (PO)
Lipopolysaccharide (LPS): 10 mg/kg (IP)

(a) 0 2 4 6 8 days
Percent survival (%)

Ctrl  LPS + Feb  LPS + Veh

(b) -15 -10 -5 5 0
Weight change (%)

Ctrl  Veh  Feb
LPS

(c) 0 30 60 90 120
BUN (mg/dl)

Ctrl  Veh  Feb
LPS

⁎⁎⁎ ⁎⁎ ⁎

(d) 0.0 0.3 0.6 0.9
Scr (mg/dl)

Ctrl  Veh  Feb
LPS

⁎⁎⁎ ⁎ ￿￿

(e) LPS + Feb  LPS + Veh  Ctrl

(f) Figure 1: Continued.
2.13. Statistical Analysis. Data are presented as the mean ± standard deviation (SD). Differences between different data means were compared by using Student’s t-test and one-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparison tests using GraphPad Prism 7. *P < 0.05 indicates that the difference is statistically significant.

3. Results

3.1. Effects of Febuxostat on Attenuating Renal Injury in SI-AKI Mice. The schedule of LPS (10 mg/kg, ip.) and febuxostat (Feb, 10 mg/kg/day, po.) administration was outlined (Figure 1(a)). We first administered febuxostat daily one week before establishing the LPS-challenged SI-AKI model. We recorded the survival of SI-AKI mice with or without febuxostat pretreatment within one week (Figure 1(b)). Control mice exhibited 100% survival. Forty-eight hours after LPS administration, 40% of septic mice died, and after another 48 h, the remaining septic mice died. In contrast, febuxostat pretreatment dramatically increased the survival rate by 90% compared to the LPS group (Figure 1(b)). Therefore, the SI-AKI mice were killed 24 h after LPS injection for the subsequent experiments.

Febuxostat pretreatment showed remarkable resistance to weight loss in SI-AKI mice (Figure 1(c)). Induction of sepsis by LPS caused a significant increase in blood urea nitrogen (BUN, Figure 1(d)) and serum creatinine (Scr, Figure 1(e)) compared to the control group. Pretreatment with febuxostat exerted a significant decrease in BUN and Scr levels compared to the LPS group (Figures 1(d) and 1(e)). The specific histopathological features of SI-AKI showed that many renal tubular epithelial cells were vacuolated, the brush border was lost and flattened, and protein cast was also observed (Figure 1(f)). After febuxostat pretreatment, renal tubular epithelial cell injury was significantly improved (Figure 1(g)).

3.2. Febuxostat Relieves Serum and Renal Tissue XO Activity, and XO Knockdown Attenuates Kidney Injury in SI-AKI Mice. Although febuxostat has shown an inhibitory effect on XO activity in other kidney injury models, this effect has not been reported in SI-AKI animal models. Consistent with the changes in renal function and histology, SI-AKI mice displayed higher XO activity in the serum and kidneys than control mice, and the increase in XO activity induced by LPS was reversed by febuxostat pretreatment (Figures 2(a) and 2(b)). Immunofluorescence assays further confirmed that the increased expression of XO in the kidney induced by LPS was inhibited by febuxostat pretreatment (Figures 2(c) and 2(d)). To further confirm the role of XO in SI-AKI, we constructed an AAV vector with XO shRNA (pAAV-shXO), and administration of pAAV-shXO significantly inhibited XO expression in the kidney (Figures 2(e)–2(j)). Serum and kidney XO activity were also decreased by XO knockdown (Figures 2(j) and 2(k)). Moreover, renal function, as indicated by BUN and Scr levels, was protected from the marked increase induced by XO knockdown in SI-AKI mice (Figures 2(l) and 2(m)). HE staining of kidney tissues from each group showed that XO knockdown dampened kidney tubular injury in SI-AKI mice (Figures 2(n) and 2(o)).

3.3. The Inhibition of XO Improves Hypoxia and ROS Production in the Kidneys of SI-AKI Mice. XO is an enzyme that utilizes molecular oxygen to produce ROS. Still it is unclear whether the inhibition of XO can improve renal hypoxia in SI-AKI mice by reducing the utilization of molecular oxygen. The hypoxia distribution in renal tubular cells can be detected by fluorescence labeling of the hypoxia probe pimonidazole, which can conjugate with intracellular thios under hypoxia and then be detected with a pimonidazole secondary antibody. The fluorescence intensity of the hypoxia signal in the kidney tissue of the SI-AKI group was the strongest, while that of the febuxostat pretreatment
Figure 2: Continued.
Figure 2: Continued.
Figure 2: Febuxostat relieves serum and renal tissue XO activity, and XO knockdown attenuates kidney injury in SI-AKI mice. (a, b) The XO activity in serum and renal tissue homogenates was measured 24 h after LPS injection. XO could oxidize xanthine and produce O$_2^{-}$, which could react with WST-8, and the color of the reaction products could be detected with a micro reader at 450 nm. (c, d) Changes in XO expression in the kidneys of SI-AKI mice were detected by immunofluorescence assay (400x magnification). (e) Timeline of AAV injection displayed. (f-i) Knockdown of XO expression was confirmed using western blot and immunofluorescence assays. (j, k) Serum and renal XO activity were evaluated. BUN and Scr were analyzed after downregulation of XO and challenge with LPS (10 mg/kg). (n, o) Representative images of kidney tissue are presented, and the injury score was graded in a double-blinded manner. *$P < 0.05$, **$P < 0.01$, and ***$P < 0.001$ vs. Ctrl; # $P < 0.05$, ## $P < 0.01$, and ### $P < 0.001$ vs. LPS+Veh or LPS+Ctrl-shR ($n = 10$). Ctrl: control; Veh: vehicle; LPS: lipopolysaccharide; Feb: febuxostat; XO: xanthine oxidase; BUN: blood urea nitrogen; Scr: serum creatinine.

3.4. Hypoxia Increased LPS-Induced XO Activity in HK-2 Cells, but the Inhibition of XO Conversely Improved Hypoxia. Since we observed the protective effect of febuxostat against renal hypoxia in SI-AKI mice in vivo, we further evaluated the relationship between XO activity and cellular hypoxia and the role of febuxostat. For this purpose, HK-2 cells were treated with LPS (10 μg/ml)+febuxostat (100 μM) and cultured under normoxic (21% O$_2$, 5% CO$_2$, and 74% N$_2$) or hypoxic (2% O$_2$, 5% CO$_2$, and 93% N$_2$) conditions for 6 h in vitro. The results from the cell counting kit-8 (CCK-8) assay showed that hypoxia for 6 h did not change the viability of HK-2 cells, which was decreased by LPS, especially under the condition of hypoxic culture (Figure 4(a)). The above results indicated that febuxostat reversed the increase in LPS-induced cytotoxicity under normoxia and hypoxia. Consistent with the results of CCK-8, LPS induced a slight increase in XO activity in HK-2 cells under normoxia and a significant increase in hypoxia, suggesting that hypoxia has a positive effect on the increase in XO activity induced by LPS (Figure 4(b)). Febuxostat inhibited the increase in XO activity induced by LPS under both normoxic and hypoxic conditions (Figure 4(b)). Importantly, the green fluorescence of the hypoxia probe showed that no obvious hypoxia occurred in HK-2 cells cultured in 21% oxygen with or without LPS+febuxostat treatment (Figures 4(c) and 4(d)). After culturing with 2% O$_2$ for 6 h, HK-2 cells showed weak green fluorescence but LPS significantly enhanced the green fluorescence brightness, while febuxostat significantly reduced LPS-induced hypoxia (Figures 4(c) and 4(d)). To further confirm the function of XO in hypoxia- and LPS-induced cell injury, we knocked down XO in vitro using siRNA (Figures 4(e) and 4(f)). Loss of XO also alleviated hypoxia- and LPS-induced cell injury (Figure 4(g)) and XO activity (Figure 4(h)) and further relieved hypoxia in HK-2 cells (Figures 4(i) and 4(j)).

3.5. The Inhibition of XO Reduced Inflammation and Apoptosis in SI-AKI Mice. Hypoxia and oxidative stress induce mitochondrial damage, which further leads to the release of inflammatory cytokines and subsequent cell death [10]. Therefore, we further focused on the effects of XO inhibition on inflammation and apoptosis in SI-AKI mice. The ELISA results showed that febuxostat pretreatment significantly reduced the levels of serum inflammatory factors such as TNF-α (Figure 5(a)), IL-1β (Figure 5(b)), and IL-6 (Figure 5(c)) in SI-AKI mice triggered by LPS.
Figure 3: Continued.
Immuno-fluorescence detection of neutrophils and macrophages in renal tissue labeled with MPO (Figures 5(d) and 5(g)) and F4/80 (Figures 5(e) and 5(h)), respectively, showed that the infiltration of neutrophils and macrophages at the outer stripe of the outer medulla of the kidneys in SI-AKI mice increased significantly. Febuxostat pretreatment remarkably reduced neutrophil and macrophage infiltration. TUNEL assay in the kidneys indicated that febuxostat pretreatment significantly decreased the number of apoptotic cells induced by LPS (Figures 5(f) and 5(i)). We further investigated the impact of XO on inflammation and cell apoptosis in SI-AKI mice by knocking down XO in the kidney using pAAV-shXO. Downregulation of XO reduced the levels of serum TNF-α (Figure 5(j)), IL-1β (Figure 5(k)), and IL-6 (Figure 5(l)) in SI-AKI mice. Furthermore, neutrophil (Figures 5(m) and 5(p)) and macrophage (Figures 5(n) and 5(q)) infiltration was also reduced by XO knockdown. Cell apoptosis in the kidney was prevented by XO downregulation, as suggested by TUNEL staining (Figures 5(o) and 5(r)).

4. Discussion

Lipopolysaccharide (LPS), which is a component of the outer membrane of gram-negative bacteria, has been the most widely studied pathogen-associated molecular pattern...
Figure 4: Continued.
(PAMP) in sepsis [28, 29]. LPS activates the Toll-like receptor to activate XO, which utilizes oxygen as a substrate to decompose hypoxanthine and xanthine into uric acid, producing superoxide and hydrogen peroxide during the reaction, and is mainly expressed during cellular stress or immune activation [30–32]. Hypoxemia caused by hemodynamic changes

Figure 4: Hypoxia increased LPS-induced XO activity in HK-2 cells, but the inhibition of XO also improved hypoxia. (a) CCK8 showing the viability of HK-2 cells treated with LPS (10 μg/ml)+febuxostat (100 μM) under normoxic (21% O2) and hypoxic (2% O2) conditions for 6 h. (b) The XO activity of HK-2 cells treated with LPS+febuxostat under normoxic and hypoxic conditions for 6 h. (c, d) The intracellular hypoxia of HK-2 cells treated with LPS+febuxostat under normoxic and hypoxic conditions for 6 h was detected by an immunofluorescence assay using a hypoxia probe (800x magnification). (e, f) Knockdown of XO in HK-2 cells was confirmed using western blotting. (g) After the knockdown of XO with siRNA transfection, HK-2 cells were stimulated with LPS with 21% or 2% oxygen. Six hours later, the cells were harvested, and cell viability was assessed with the CCK8 method. (h) XO activity was assayed with the same method as in (b). (i, j) The intracellular hypoxia of HK-2 cells treated with LPS under normoxic and hypoxic conditions for 6 h was detected by an immunofluorescence assay using a hypoxia probe (800x magnification). Scale bar = 20 μm. *P < 0.05, **P < 0.01, and ***P < 0.001 vs. control; #P < 0.05, ##P < 0.01, and ###P < 0.001 vs. LPS+Veh or LPS+Ctrl-siR (n = 10). Ctrl: control; Veh: vehicle; LPS: lipopolysaccharide; Feb: febuxostat; XO: xanthine oxidase.
tubular epithelial cells by inhibiting XO activity, thus alleviating inflammation and apoptosis in SI-AKI mice. (a–c) The levels of TNF-α, IL-1β, and IL-6 in renal homogenates of SI-AKI mice were detected by ELISA. (d, g) Immunofluorescence detection of neutrophils in the kidneys of SI-AKI mice by anti-MPO antibody (400x magnification). (e, h) Immunofluorescence detection of macrophages in the kidneys of SI-AKI mice by anti-F4/80 antibody (400x magnification). (f, i) Representative TUNEL-stained sections of the kidney in SI-AKI mice (400x magnification). Semic quantitative analysis of TUNEL-positive cells in each group is also displayed. (j–l) After the downregulation of XO, mice were treated with LPS (10 mg/kg), and the levels of TNF-α, IL-1β, and IL-6 in renal homogenates of SI-AKI mice were detected by ELISA. (m and p, n and q) After knockdown of XO with pAAV-shRNA, immunofluorescence detection of neutrophils and macrophages in the kidneys of SI-AKI mice by anti-MPO and anti-F4/80 antibodies (400x magnification). (o, r) Kidney cell apoptosis was analyzed with TUNEL staining in SI-AKI mice after XO knockdown. Scale bar = 100 μm. *P < 0.05, **P < 0.01, and ***P < 0.001 vs. control; #P < 0.05, ##P < 0.01, and ###P < 0.001 vs. LPS+Veh or LPS+Ctrl-shR (n = 10). Ctrl: control; Veh: vehicle; LPS: lipopolysaccharide; Feb: febuxostat; TNF: tumor necrosis factor; IL: interleukin; MPO: myeloperoxidase; TUNEL: terminal deoxynucleotidyl transferase dUTP nick-end labeling.

In sepsis can also activate XO, which is widespread in ischemia–reperfusion models [8, 17, 20, 21, 33]. Several experimental and clinical studies have proven that XO activity has proinflammatory and prooxidative effects and can mediate vascular and endothelial dysfunction. The inhibition of XO by allopurinol or Feb has a protective effect [14, 15, 17–21, 33, 34]. In this study, we found that febuxostat, an XO-specific inhibitor, and knockdown of XO expression with pAAV-shXO showed antioxidant stress and anti-inflammatory effects and weakened the local hypoxia of renal tubular epithelial cells by inhibiting XO activity, thus alleviating inflammation and apoptosis in SI-AKI. The results of inhibition of XO in HK-2 cells with febuxostat and XO-siRNA in vitro showed that the downregulation of XO remarkably reduced the hypoxia condition in HK-2 cells induced by LPS and 2% oxygen. Taken together, our results indicated important roles of XO in oxidative stress- and hypoxia-induced injury in SI-AKI.

Currently, XO inhibitors approved by the US Food and Drug Administration (FDA) include three drugs, allopurinol, febuxostat, and topiroxostat, which all show antioxidant, anti-inflammatory, and renoprotective effects in addition to reducing uric acid [33]. Moreover, allopurinol and febuxostat...
have been confirmed to play an important role in myocardial mechnanoenergetic uncoupling. Febuxostat is superior to allopurinol in reducing systolic blood pressure, pulse-wave velocity, and left ventricular mass index in hyperuricemic patients undergoing cardiac surgery [35]. Moreover, febuxostat was more effective and faster than allopurinol in achieving the serum uric acid target in patients with gout [36]. Similarly, febuxostat has an advantage over topiroxostat in cardiorenal protection in hyperuricemic patients with cardiovascular disease [37, 38]. Recently, there have been only two reports on the treatment of SI-AKI with febuxostat showing that febuxostat improves the prognosis of SI-AKI animals through antioxidant stress and anti-inflammation [20, 21]. In this study, we also confirmed that pretreatment with febuxostat or kidney knockdown of XO by shRNA in vivo significantly improved the prognosis of SI-AKI mice by reducing the levels of BUN, Scr, TNF-α, IL-6, and IL-1β in peripheral blood and by improving histological damage, reducing kidney tubular cell apoptosis and ROS production, and inhibiting infiltration of neutrophils and macrophages in the kidneys. This suggests that the inhibition of XO has a nephroprotective effect on SI-AKI through anti-inflammation, antioxidant stress, and antiapoptosis.

Sepsis is often accompanied by organ dysfunction, poor tissue perfusion, or hypotension, which is bound to ischemia/hypoxia of damaged organs [2–6]. Renal dysfunction in sepsis is usually secondary to septic shock and sometimes to hypovolemia [39, 40]. AKI, including endotoxemia, can reduce tissue oxygen delivery and increase renal tissue oxygen consumption, resulting in renal medullary hypoxia, which can be the main driver of a cascade of events leading to renal tubular dysfunction, vascular injury, and cell injury [41]. This study found that LPS induced significant hypoxia in renal tubular epithelial cells through hypoxia probe fluorescence detection. However, pretreatment with febuxostat or kidney knockdown of XO by shRNA in vivo significantly improved renal hypoxia in SI-AKI mice, suggesting that the inhibition of XO elicits a favorable effect on alleviating renal medullary hypoxia in SI-AKI mice. We further evaluated the effect of pharmacologic (febuxostat) and genetic (XO siRNA) inhibition on XO activity and the viability of HK-2 cells under LPS and hypoxia in vitro. Our results showed that LPS caused a slight increase in XO activity under normoxia and a significant increase under hypoxia, accompanied by consistent changes in the degree of hypoxia, suggesting that the effect of LPS on XO activity is closely related to cell hypoxia. Importantly, for HK-2 cells treated with LPS, pharmacologic and genetic inhibition of XO improved cell hypoxia at 2% oxygen concentration and reversed the decrease in cell viability induced by LPS, suggesting the positive effect of inhibition of XO in improving cell hypoxia.

Hypoxia-inducible factor (HIF) is a cellular oxygen sensor that is a heterodimeric protein composed of an α subunit and a β subunit [42]. Under normoxia, the α subunit is unstable, degraded by the ubiquitin–proteasome system and does not function [42]. Under hypoxia, stabilization of the α subunit results in the formation of a dimer with the β subunit, which translocates to the nucleus, initiating mRNA synthesis for multiple genes [42, 43]. For example, it can upregulate erythropoietin and endothelial nitric oxide synthase (eNOS) and ameliorate tissue hypoxia [22]. However, HIF can be a double-edged sword because early onset of renal medullary hypoxia in sepsis prolongs the phases of tissue hypoxia, leading to the destabilization of HIF that aggravates oxidative and nitrosative injuries, culminating in AKI [44]. In addition, excessive production of HIF in response to prolonged hypoxia in severe sepsis can lead to excessive production of vasoconstrictive and ROS-induced proteins, such as inducible nitric oxide synthase (iNOS), thereby promoting fibrogenesis [22]. Although our study did not further explore the advantages and disadvantages of high expression of HIF-1α in the kidneys of SI-AKI mice, the decrease in HIF-1α expression in the kidneys of mice with pharmacological and genetic inhibition of XO did not rule out the improvement of cellular hypoxia increased the degradation of HIF-1α, which further enriched the effect of XO inhibition in improving renal medulla hypoxia.

5. Conclusions

In summary, we proposed for the first time that the nephroprotective effect of inhibiting XO in SI-AKI models occurred at least partly through inhibiting XO activity to reduce renal hypoxia, thereby decreasing oxidative stress, inflammation, and apoptosis and ultimately attenuating the pathological process of SI-AKI. Although the specific regulatory pathway of XO inhibition to improve cellular hypoxia has still not been comprehensively illuminated, the current work might provide novel insight into the choice of drugs for the prevention and treatment of SI-AKI.

Abbreviations

AKI: Acute kidney injury
SI-AKI: Sepsis-induced AKI
LPS: Lipopolysaccharide
Feb: Febuxostat
ROS: Reactive oxygen species
XO: Xanthine oxidase
CKD: Chronic kidney disease
BUN: Blood urea nitrogen
Scr: Serum creatinine
HIF: Hypoxia-inducible factor
DHE: Dihydroethidium
CLSM: Confocal laser-scanning microscope
MPO: Myeloperoxidase
TNF: Tumor necrosis factor
IL: Interleukin
TUNEL: Terminal deoxynucleotidyl transferase dUTP nick-end labeling.

Data Availability

All data related to this paper may also be requested from the corresponding authors (email: xjsnlhb@fmmu.edu.cn).
Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Authors’ Contributions

Ting-ting Wang, Yi-wei Du, Wen Wang, and Xiang-nan Li contributed equally to this work.

Acknowledgments

This work was supported by the Subject Platform and Technology Innovation Development Foundation of Tangdu Hospital (grant numbers 2019QYTS003, 2020XKPT014, 2021QYJC-001, 2021SHRC048, 2021SHRC050, and 2021SHRC051).

References

[1] J. A. Kellum, P. Romagnani, G. Ashuntantang, C. Ronco, A. Zarbock, and H. J. Anders, “Acute kidney injury,” Nat. Rev. Dis. Prim., vol. 7, no. 1, 2021.

[2] C. L. Manrique-Caballero, G. Del Rio-Pertuz, and H. Gomez, “Sepsis-associated acute kidney injury,” Critical Care Clinics, vol. 37, no. 2, pp. 279–301, 2021.

[3] T. Hellman, P. Uusalo, and M. J. Järvisalo, “Renal replacement techniques in septic shock,” International Journal of Molecular Sciences, vol. 22, no. 19, p. 10238, 2021.

[4] K. Kalantari and M. H. Rosner, “Recent advances in the pharmacological management of sepsis-associated acute kidney injury,” Expert Review of Clinical Pharmacology, vol. 14, no. 11, pp. 1401–1411, 2021.

[5] J. L. Koyner, “Sepsis and kidney injury,” Contributions to Nephrology, vol. 199, pp. 56–70, 2021.

[6] A. Stasi, A. Intini, C. Divella et al., “Emerging role of lipopolysaccharide binding protein in sepsis-induced acute kidney injury,” Nephrology, Dialysis, Transplantation, vol. 32, no. 1, pp. 24–31, 2016.

[7] K. Doi, A. Leelahavanichkul, P. S. T. Yuen, and R. A. Star, “Animal models of sepsis and sepsis-induced kidney injury,” The Journal of Clinical Investigation, vol. 119, no. 10, pp. 2868–2878, 2009.

[8] H. M. Schmidt, E. E. Kelley, and A. C. Straub, “The impact of xanthine oxidase (XO) on hemolytic diseases,” Redox Biology, vol. 21, p. 101072, 2019.

[9] S. S. Al-Shenri, J. A. Duley, and N. Bansal, “Xanthine oxidase-lactoperoxidase system and innate immunity: biochemical actions and physiological roles,” Redox Biology, vol. 34, p. 101524, 2020.

[10] M. G. Battelli, L. Polito, M. Bortolotti, and A. Bolognesi, “Xanthine oxidoreductase-derived reactive species: physiological and pathological effects,” Oxidative Medicine and Cellular Longevity, vol. 2016, 8 pages, 2016.

[11] N. Cantu-Medellin and E. E. Kelley, “Xanthine oxidoreductase-catalyzed reactive species generation: a process in critical need of reevaluation,” Redox Biology, vol. 1, no. 1, pp. 353–358, 2013.

[12] H. Fu, J. Zhang, and M. Huang, “Topiroxostat ameliorates oxidative stress and inflammation in sepsis-induced lung injury,” Zeitschrift fur Naturforsch. - Sect. C Journal of Biosciences, vol. 75, no. 11–12, pp. 425–431, 2020.

[13] M. Damarla, L. F. Johnston, G. Liu et al., “XOR inhibition with febuxostat accelerates pulmonary endothelial barrier recovery and improves survival in lipopolysaccharide-induced murine sepsis,” Physiological Reports, vol. 5, no. 15, pp. 1–10, 2017.

[14] P. H. F. Gois, D. Canale, R. A. Volpini et al., “Allopurinol attenuates rhabdomyolysis-associated acute kidney injury: renal and muscular protection,” Free Radical Biology & Medicine, vol. 101, pp. 176–189, 2016.

[15] T. Erol, A. Tekin, M. T. Katirci et al., “Efficacy of allopurinol pretreatment for prevention of contrast-induced nephropathy: a randomized controlled trial,” International Journal of Cardiology, vol. 167, no. 4, pp. 1396–1399, 2013.

[16] N. Yabuuchi, H. Hou, N. Gunda, Y. Narita, H. Jono, and H. Saito, “Suppressed hepatic production of indoxyl sulfate attenuates cisplatin-induced acute kidney injury in sulfotransferase 1a1-deficient mice,” International Journal of Molecular Sciences, vol. 22, no. 4, p. 1764, 2021.

[17] K. Fujii, A. Kubo, K. Miyashita et al., “Xanthine oxidase inhibitor ameliorates postischemic renal injury in mice by promoting resynthesis of adenine nucleotides,” JCI Insight, vol. 4, no. 22, 2019.

[18] K. J. Yang, J. H. Kim, Y. K. Chang, C. W. Park, S. Y. Kim, and Y. A. Hong, “Inhibition of xanthine oxidoreductase protects against contrast-induced renal tubular injury by activating adenosine monophosphate-activated protein kinase,” Free Radical Biology & Medicine, vol. 145, pp. 209–220, 2019.

[19] A. N. A. Fahmi, G. S. G. Shehatou, A. M. Shebl, and H. A. Salem, “Febuxostat exerts dose-dependent renoprotection in rats with cisplatin-induced acute renal injury,” Naunyn-Schmiedeberg’s Archives of Pharmacology, vol. 389, no. 8, pp. 819–830, 2016.

[20] M. F. de Paula Ramos, C. V. Razvickas, F. T. Borges, and N. Schor, “Xanthine oxidase inhibitors and sepsis,” International Journal of Immunopathology and Pharmacology, vol. 32, p. 205873841877221, 2018.

[21] Y. F. Ibrahim, R. R. Fadl, S. A. E. Ibrahim, M. F. Gayyed, A. M. Bayoumi, and M. M. M. Refaie, “Protective effect of febuxostat in sepsis-induced liver and kidney injuries after cecal ligation and puncture with the impact of xanthine oxidase, interleukin 1β, and c-Jun N-terminal kinases,” Human & Experimental Toxicology, vol. 39, no. 7, pp. 906–919, 2020.

[22] C. P. Ow, A. Trask-Marino, A. H. Betrie, R. G. Evans, C. N. May, and Y. R. Lankadeva, “Targeting oxidative stress in septic acute kidney injury: From theory to practice,” Journal of Clinical Medicine, vol. 10, no. 17, p. 3798, 2021.

[23] H. Scholz, F. J. Boivin, K. M. Schmidt-Ott et al., “Kidney physiology and susceptibility to acute kidney injury: implications for renoprotection,” Nature Reviews. Nephrology, vol. 17, no. 5, pp. 335–349, 2021.

[24] C. J. Rocca, S. N. Ur, F. Harrison, and S. Cherqui, “RAAV9 combined with renal vein injection is optimal for kidney-targeted gene delivery: conclusion of a comparative study,” Gene Therapy, vol. 21, no. 6, pp. 618–628, 2014.

[25] M. H. Ho, C. H. Yen, T. H. Hsieh et al., “CCL5 via GPRX1 activation protects hippocampal memory function after mild traumatic brain injury,” Redox Biology, vol. 46, article 102067, 2021.

[26] L. Zhou, P. Yu, T. T. Wang et al., “Polydatin attenuates cisplatin-induced acute kidney injury by inhibiting ferroptosis,” Oxidative Medicine and Cellular Longevity
H. B. Liu, Q. H. Meng, C. Huang, J. B. Wang, and X. W. Liu, "Nephroprotective effects of polydatin against ischemia/reperfusion injury: a role for the PI3K/Akt signal pathway," Oxidative Medicine and Cellular Longevity, vol. 2015, 13 pages, 2015.

G. Gorecki, D. Cochior, C. Moldovan, and E. Rusu, "Molecular mechanisms in septic shock (review)," Experimental and Therapeutic Medicine, vol. 22, no. 4, pp. 1–5, 2021.

C. Lelubre and J. L. Vincent, "Mechanisms and treatment of organ failure in sepsis," Nature Reviews. Nephrology, vol. 14, no. 7, pp. 417–427, 2018.

A. Sezai, M. Soma, K. I. Nakata et al., "Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD)," Journal of Cardiology, vol. 66, no. 4, pp. 298–303, 2015.

G. Desideri, M. Rajzer, M. Gerritsen et al., "Effects of intensive urate lowering therapy with febuxostat in comparison with allopurinol on pulse wave velocity in patients with gout and increased cardiovascular risk: the FORWARD study," Eur Heart J Cardiovasc Pharmacother, vol. 8, no. 3, pp. 236–242, 2022.

A. Sezai, S. Unosawa, M. Taoka, S. Osaka, H. Sekino, and M. Tanaka, "Changeover trial of febuxostat and topiroxostat for hyperuricemia with cardiovascular disease: sub-analysis for chronic kidney disease (trofeo ckd trial)," Annals of Thoracic and Cardiovascular Surgery, vol. 26, no. 4, pp. 202–208, 2020.

A. Sezai, K. Obata, K. Abe, S. Kanno, and H. Sekino, "Cross-over trial of febuxostat and topiroxostat for hyperuricemia with cardiovascular disease (TROFEO trial)," Circulation Journal, vol. 81, no. 11, pp. 1707–1712, 2017.

E. H. Post, J. A. Kellum, R. Bellomo, and J. L. Vincent, "Renal perfusion in sepsis: from macro- to microcirculation," Kidney International, vol. 91, no. 1, pp. 45–60, 2017.

C. Ronco, R. Bellomo, and J. A. Kellum, "Acute kidney injury," Lancet, vol. 394, no. 10121, pp. 1949–1964, 2019.

S. Peerapornratana, C. L. Manrique-Caballero, H. Gómez, and J. A. Kellum, "Acute kidney injury from sepsis: current concepts, epidemiology, pathophysiology, prevention and treatment," Kidney International, vol. 96, no. 5, pp. 1083–1099, 2019.